. Author manuscript; available in PMC: 2015 Feb 1.

Published in final edited form as: J Endocrinol. 2014 Jul;222(1):27–41. doi: 10.1530/JOE-13-0455

Table 2.

Adiposity, serum leptin and BAT UPC1 levels following simultaneous VTA leptin overexpression and MBH leptin antagonist overexpression in Exp. 2.

	rAAV-Control	rAAV-Leptin into VTA	rAAV-Leptin into VTA rAAV antagonist into MBH
Adiposity, g	7.01 ± 0.45^a	1.40 ± 0.54^b	3.52 ± 0.76^c
Serum Leptin, ng/ml	4.1 ± 0.3^a	1.4 ± 0.2^b	2.0 ± 0.4^b
UCP1/ μg Arbitrary units	100 ± 13.7^a	207.4 ± 16.7^c	201.8 ± 27.0^c

Data represent the mean ± SE of 7-8 rats per group.

Adiposity represents the sum of perirenal, retroperitoneal and epididymal white adipose tissues at death.

P<0.0001 (Adiposity and Serum leptin) or P<0.002 (UCP1) for difference among groups by one-way ANOVA.

The value of UCP1, expressed as UCP1/ μg BAT protein, in rAAV-Control for is arbitrarily set to 100 with SE adjusted proportionally with remaining groups normalized to the level in rAAV-Control.

P<0.001 for difference from control group by Newman-Keuls post-hoc analysis.

P<0.01 for difference from control group by Newman-Keuls post-hoc analysis.